Banete Andra, Gee Katrina, Basta Sameh
Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
J Leukoc Biol. 2022 Feb;111(2):401-413. doi: 10.1002/JLB.3A0520-293RR. Epub 2021 May 19.
Macrophages (Mϕ) are highly plastic, and can acquire a variety of functional phenotypes depending on the presence of different stimuli in their local environment. Mφ stimulated by interleukin (IL)-4 induce an alternative activation state and function as anti-inflammatory cells and promote tissue repair. However, there is overwhelming evidence that IL-4 can play a role in promoting inflammation. In asthma and allergic inflammation, IL-4 mediates proinflammatory responses that lead to tissue damage. Thus the effect of IL-4 on the outcome of the immune responses is greatly influenced by other cofactors and cytokines present in the microenvironment. R848 (resiquimod), a TLR7/8 agonist is a novel vaccine adjuvant, triggering a strong Th1-skewed response but its efficacy as a vaccine adjuvant shows variable results. It is not currently known whether the presence of IL-4 can dampen or enhance immunity in response to TLR7 agonists. In the present study, we sought to investigate the impact of IL-4-induced Mφ polarization on the outcome of R848 stimulation. The activation marker expression and production of cytokines were measured in murine spleen-derived Mφ. Protein expression levels of innate recognition molecules and transcription factors involved, including retinoic-acid inducible gene I, mitochondrial antiviral signaling protein, stimulator of interferon genes (STING), and IFN regulatory factors were evaluated in activated Mφ. These play a crucial role in the control of viral replication and optimal CD8+ T cell priming. We report that sustained priming with IL-4 alone promotes an antiviral response in Mφ, and enhances proinflammatory responses to R848 treatment. This highlights the need for better understanding of IL-4 proinflammatory functions and its potential use as a broad-acting antiviral in combination with R848 may be used in combination with other therapies to target the innate arm of immunity against emerging infections.
巨噬细胞(Mϕ)具有高度可塑性,可根据其局部环境中不同刺激的存在获得多种功能表型。受到白细胞介素(IL)-4刺激的Mφ会诱导一种替代性激活状态,并作为抗炎细胞发挥作用,促进组织修复。然而,有大量证据表明IL-4可在促进炎症中发挥作用。在哮喘和过敏性炎症中,IL-4介导导致组织损伤的促炎反应。因此,IL-4对免疫反应结果的影响受到微环境中其他辅助因子和细胞因子的极大影响。R848(瑞喹莫德)是一种TLR7/8激动剂,是一种新型疫苗佐剂,可引发强烈的Th1偏向反应,但其作为疫苗佐剂的功效显示出不同的结果。目前尚不清楚IL-4的存在是否会抑制或增强对TLR7激动剂的免疫反应。在本研究中,我们试图研究IL-4诱导的Mφ极化对R848刺激结果的影响。在小鼠脾脏来源的Mφ中测量激活标志物的表达和细胞因子的产生。在活化的Mφ中评估参与的天然识别分子和转录因子的蛋白质表达水平,包括视黄酸诱导基因I、线粒体抗病毒信号蛋白、干扰素基因刺激物(STING)和IFN调节因子。这些在控制病毒复制和最佳CD8 + T细胞启动中起关键作用。我们报告说,单独用IL-4持续启动可促进Mφ中的抗病毒反应,并增强对R848治疗的促炎反应。这突出表明需要更好地了解IL-4的促炎功能,其作为一种广泛作用的抗病毒药物与R848联合使用的潜力可能与其他疗法联合使用,以靶向针对新出现感染的先天性免疫分支。